Our results demonstrate that single-dose immunization with ZIKV M/E vaccine followed by OX40 and 4-1BB agonist Ab administration on consecutive days markedly boosts the production of ZIKV-specific polyfunctional and cytotoxic CD8+ T cell responses and prolongs the ability of these T cells to reduce viral loads following infection. The gene discussed is CD8A; the disease is infection.